Base de dados : MEDLINE
Pesquisa : C14.907.940.897.249.249 [Categoria DeCS]
Referências encontradas : 1892 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 190 ir para página                         

  1 / 1892 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29203755
[Au] Autor:Zhdan VМ; Kitura YМ; Kitura OY; Babanina MY; Tkachenko MV; Lebid VG
[Ad] Endereço:Higher State Educational Establishment Of Ukraine "Ukrainian Medical Stomatological Academy", Poltava, Ukraine.
[Ti] Título:Churg-strauss syndrome: a case report.
[So] Source:Wiad Lek;70(5):992-994, 2017.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:A clinical case of Churg-Strauss syndrome has been reported on the 53-year-old female patient Ts. with bronchial asthma and allergic rhinitis. The main clinical signs and syndromes depending on the stage of the disease are presented, as well as therapeutic treatment of patients with this disease.
[Mh] Termos MeSH primário: Síndrome de Churg-Strauss/diagnóstico
Síndrome de Churg-Strauss/terapia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  2 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29016646
[Au] Autor:Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
[Ad] Endereço:Nephrology Unit, University Hospital of Parma, Italy.
[Ti] Título:Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
[So] Source:PLoS One;12(10):e0185880, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is based on remission-induction and remission-maintenance. Methotrexate is a widely used immunosuppressant but only a few studies explored its role for maintenance in AAV. This trial investigated the efficacy and safety of methotrexate as maintenance therapy for AAV. METHODS: In this single-centre, open-label, randomised trial we compared methotrexate and cyclophosphamide for maintenance in AAV. We enrolled patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), the latter with poor-prognosis factors and/or peripheral neuropathy. Remission was induced with cyclophosphamide. At remission, the patients were randomised to receive methotrexate or to continue with cyclophosphamide for 12 months; after treatment, they were followed for another 12 months. The primary end-point was relapse; secondary end-points included renal outcomes and treatment-related toxicity. RESULTS: Of the 94 enrolled patients, 23 were excluded during remission-induction or did not achieve remission; the remaining 71 were randomised to cyclophosphamide (n = 33) or methotrexate (n = 38). Relapse frequencies at months 12 and 24 after randomisation were not different between the two groups (p = 1.00 and 1.00). Relapse-free survival was also comparable (log-rank test p = 0.99). No differences in relapses were detected between the two treatments when GPA+MPA and EGPA were analysed separately. There were no differences in eGFR at months 12 and 24; proteinuria declined significantly (from diagnosis to month 24) only in the cyclophosphamide group (p = 0.0007). No significant differences in adverse event frequencies were observed. CONCLUSIONS: MTX may be effective and safe for remission-maintenance in AAV. TRIAL REGISTRATION: clinicaltrials.gov NCT00751517.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico
Síndrome de Churg-Strauss/tratamento farmacológico
Ciclofosfamida/uso terapêutico
Granulomatose com Poliangiite/tratamento farmacológico
Imunossupressores/uso terapêutico
Metotrexato/uso terapêutico
Poliangiite Microscópica/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/imunologia
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/mortalidade
Anticorpos Anticitoplasma de Neutrófilos/sangue
Síndrome de Churg-Strauss/complicações
Síndrome de Churg-Strauss/imunologia
Síndrome de Churg-Strauss/mortalidade
Feminino
Granulomatose com Poliangiite/complicações
Granulomatose com Poliangiite/imunologia
Granulomatose com Poliangiite/mortalidade
Seres Humanos
Masculino
Poliangiite Microscópica/complicações
Poliangiite Microscópica/imunologia
Poliangiite Microscópica/mortalidade
Meia-Idade
Segurança do Paciente
Seleção de Pacientes
Doenças do Sistema Nervoso Periférico/complicações
Doenças do Sistema Nervoso Periférico/tratamento farmacológico
Doenças do Sistema Nervoso Periférico/imunologia
Doenças do Sistema Nervoso Periférico/mortalidade
Proteinúria/complicações
Proteinúria/tratamento farmacológico
Proteinúria/imunologia
Proteinúria/mortalidade
Distribuição Aleatória
Recidiva
Indução de Remissão
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Immunosuppressive Agents); 8N3DW7272P (Cyclophosphamide); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171011
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185880


  3 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28678392
[Au] Autor:Puéchal X; Pagnoux C; Baron G; Quémeneur T; Néel A; Agard C; Lifermann F; Liozon E; Ruivard M; Godmer P; Limal N; Mékinian A; Papo T; Ruppert AM; Bourgarit A; Bienvenu B; Geffray L; Saraux JL; Diot E; Crestani B; Delbrel X; Sailler L; Cohen P; Le Guern V; Terrier B; Groh M; Le Jeunne C; Mouthon L; Ravaud P; Guillevin L; French Vasculitis Study Group
[Ad] Endereço:National Referral Center for Rare Systemic and Autoimmune Diseases, Department of Internal Medicine, Université Paris Descartes, Hôpital Cochin, AP-HP, Paris, France.
[Ti] Título:Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.
[So] Source:Arthritis Rheumatol;69(11):2175-2186, 2017 Nov.
[Is] ISSN:2326-5205
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: In most patients with nonsevere systemic necrotizing vasculitides (SNVs), remission is achieved with glucocorticoids alone, but one-third experience a relapse within 2 years. This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN). METHODS: All patients included in this double-blind trial received glucocorticoids, gradually tapered over 12 months, and were randomized to receive AZA or placebo for 12 months, with stratification according to SNV (EGPA or MPA/PAN). The primary end point was the combined rate of remission induction failures and minor or major relapses at month 24. RESULTS: Ninety-five patients (51 with EGPA, 25 with MPA, and 19 with PAN) met the inclusion criteria, were randomized, and received at least 1 dose of AZA (n = 46) or placebo (n = 49). At month 24, 47.8% of the patients receiving AZA versus 49% of the patients receiving placebo had remission induction failures or relapses (P = 0.86). Secondary end points were comparable between the AZA and placebo arms. These included initial remission rate (95.7% versus 87.8%), total relapse rate (44.2% versus 40.5%), and glucocorticoid use. Two patients in the placebo arm died; 22 patients in the AZA arm (47.8%) and 23 patients in the placebo arm (46.9%) experienced ≥1 severe adverse event. For EGPA patients, the primary end point (48% in the AZA arm versus 46.2% in the placebo arm) and the percent of patients who experienced asthma/rhinosinusitis exacerbations (24% in the AZA arm versus 19.2% in the placebo arm) were comparable between treatment arms. CONCLUSION: Addition of AZA to glucocorticoids for the induction of remission of nonsevere SNVs does not improve remission rates, lower relapse risk, spare steroids, or diminish the EGPA asthma/rhinosinusitis exacerbation rate.
[Mh] Termos MeSH primário: Azatioprina/uso terapêutico
Síndrome de Churg-Strauss/tratamento farmacológico
Glucocorticoides/uso terapêutico
Imunossupressores/uso terapêutico
Poliangiite Microscópica/tratamento farmacológico
Poliarterite Nodosa/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Asma/induzido quimicamente
Progressão da Doença
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Recidiva
Indução de Remissão
Rinite/induzido quimicamente
Sinusite/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Immunosuppressive Agents); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE
[do] DOI:10.1002/art.40205


  4 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28514601
[Au] Autor:Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ; EGPA Mepolizumab Study Team
[Ad] Endereço:From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center, Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridg
[Ti] Título:Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
[So] Source:N Engl J Med;376(20):1921-1932, 2017 05 18.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis. Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with polyangiitis. METHODS: In this multicenter, double-blind, parallel-group, phase 3 trial, we randomly assigned participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had received treatment for at least 4 weeks and were taking a stable prednisolone or prednisone dose to receive 300 mg of mepolizumab or placebo, administered subcutaneously every 4 weeks, plus standard care, for 52 weeks. The two primary end points were the accrued weeks of remission over a 52-week period, according to categorical quantification, and the proportion of participants in remission at both week 36 and week 48. Secondary end points included the time to first relapse and the average daily glucocorticoid dose (during weeks 48 through 52). The annualized relapse rate and safety were assessed. RESULTS: A total of 136 participants underwent randomization, with 68 participants assigned to receive mepolizumab and 68 to receive placebo. Mepolizumab treatment led to significantly more accrued weeks of remission than placebo (28% vs. 3% of the participants had ≥24 weeks of accrued remission; odds ratio, 5.91; 95% confidence interval [CI], 2.68 to 13.03; P<0.001) and a higher percentage of participants in remission at both week 36 and week 48 (32% vs. 3%; odds ratio, 16.74; 95% CI, 3.61 to 77.56; P<0.001). Remission did not occur in 47% of the participants in the mepolizumab group versus 81% of those in the placebo group. The annualized relapse rate was 1.14 in the mepolizumab group, as compared with 2.27 in the placebo group (rate ratio, 0.50; 95% CI, 0.36 to 0.70; P<0.001). A total of 44% of the participants in the mepolizumab group, as compared with 7% of those in the placebo group, had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day during weeks 48 through 52 (odds ratio, 0.20; 95% CI, 0.09 to 0.41; P<0.001). The safety profile of mepolizumab was similar to that observed in previous studies. CONCLUSIONS: In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more weeks in remission and a higher proportion of participants in remission than did placebo, thus allowing for reduced glucocorticoid use. Even so, only approximately half the participants treated with mepolizumab had protocol-defined remission. (Funded by GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT02020889 .).
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Síndrome de Churg-Strauss/tratamento farmacológico
Fatores Imunológicos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Anticorpos Monoclonais Humanizados/efeitos adversos
Síndrome de Churg-Strauss/imunologia
Intervalo Livre de Doença
Método Duplo-Cego
Quimioterapia Combinada
Eosinófilos
Feminino
Glucocorticoides/uso terapêutico
Seres Humanos
Fatores Imunológicos/efeitos adversos
Injeções Subcutâneas/efeitos adversos
Análise de Intenção de Tratamento
Contagem de Leucócitos
Masculino
Meia-Idade
Recidiva
Indução de Remissão
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Glucocorticoids); 0 (Immunologic Factors); 90Z2UF0E52 (mepolizumab)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171118
[Lr] Data última revisão:
171118
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170518
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1702079


  5 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28365634
[Au] Autor:Schiefermueller J; Alaour B; Calver A; Curzen N
[Ad] Endereço:Papworth Hospital, Cambridge, UK juergen@schiefermueller.com.
[Ti] Título:Lesson of the month 1: Beware the atypical presentation: eosinophilic granulomatosis with polyangiitis presenting as acute coronary syndrome.
[So] Source:Clin Med (Lond);17(2):180-182, 2017 Apr.
[Is] ISSN:1473-4893
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We describe the case of a 45-year-old woman presenting with troponin positive cardiac-sounding chest pain. An initial emergency angiogram demonstrated two vessel coronary disease, including a distal right coronary artery occlusion. No percutaneous coronary intervention was performed and the patient was treated medically. At re-presentation with further pain a few days later, coronary angiography demonstrated no significant coronary lesions. After consideration of other multisystem symptoms and raised eosinophil count, the patient was diagnosed with eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) presenting with coronary arteritis. This case should remind physicians to be vigilant and to consider non-atherosclerotic causes of acute coronary syndrome presentation, which should not always result in a stent.
[Mh] Termos MeSH primário: Síndrome Coronariana Aguda
Granulomatose com Poliangiite
[Mh] Termos MeSH secundário: Síndrome de Churg-Strauss
Angiografia Coronária
Feminino
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170403
[St] Status:MEDLINE
[do] DOI:10.7861/clinmedicine.17-2-180


  6 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28339660
[Au] Autor:Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
[Ad] Endereço:Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.
[Ti] Título:Eculizumab in secondary atypical haemolytic uraemic syndrome.
[So] Source:Nephrol Dial Transplant;32(3):466-474, 2017 03 01.
[Is] ISSN:1460-2385
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. Methods: We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 × 10 9 /L) and haemoglobin, disappearance of all the markers of microangiopathic haemolytic anaemia (MAHA), and improvement of renal function, with a ≥25% reduction of serum creatinine from the onset of eculizumab administration. Results: Twenty-nine patients with secondary aHUS (15 drug-induced, 8 associated with systemic diseases, 2 with postpartum, 2 with cancer-related, 1 associated with acute humoral rejection and 1 with intestinal lymphangiectasia) were included in this study. The reason to initiate eculizumab treatment was worsening of renal function and persistence of TMA despite treatment of the TMA cause and plasmapheresis. All patients showed severe MAHA and renal function impairment (14 requiring dialysis) prior to eculizumab treatment and 11 presented severe extrarenal manifestations. A rapid resolution of the TMA was observed in 20 patients (68%), 15 of them showing a ≥50% serum creatinine reduction at the last follow-up. Comprehensive genetic and molecular studies in 22 patients identified complement pathogenic variants in only 2 patients. With these two exceptions, eculizumab was discontinued, after a median of 8 weeks of treatment, without the occurrence of aHUS relapses. Conclusion: Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Síndrome Hemolítico-Urêmica Atípica/tratamento farmacológico
Inativadores do Complemento/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Síndrome Hemolítico-Urêmica Atípica/etiologia
Síndrome Hemolítico-Urêmica Atípica/metabolismo
Síndrome de Churg-Strauss/complicações
Creatinina/metabolismo
Feminino
Seres Humanos
Imunossupressores/efeitos adversos
Testes de Função Renal
Lúpus Eritematoso Sistêmico/complicações
Masculino
Meia-Idade
Plasmaferese
Contagem de Plaquetas
Recidiva
Insuficiência Renal/etiologia
Insuficiência Renal/metabolismo
Escleroderma Sistêmico/complicações
Microangiopatias Trombóticas/tratamento farmacológico
Microangiopatias Trombóticas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Complement Inactivating Agents); 0 (Immunosuppressive Agents); A3ULP0F556 (eculizumab); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE
[do] DOI:10.1093/ndt/gfw453


  7 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28339364
[Au] Autor:Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
[Ad] Endereço:Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
[Ti] Título:Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis.
[So] Source:Clin Exp Rheumatol;35 Suppl 103(1):111-118, 2017 Mar-Apr.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: We reclassified Korean patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) into 3 categories of AAV including MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis, and investigated clinical and prognostic features. METHODS: We reviewed the medical records of 133 patients with microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and eosinophilic GPA (EGPA), who had either myeloperoxidase (MPO)-ANCA, proteinase 3 (PR3)-ANCA or no ANCA, and who had ever achieved the first remission. We compared clinical manifestations, initial Birmingham vasculitis activity score (BVAS) and five factor score (FFS), and relapse rates. RESULTS: Patients with ANCA-negative vasculitis had the youngest mean age at diagnosis (50.0 years old) among AAV categories. General, cutaneous and renal manifestations were commonly observed in MPO-ANCA vasculitis, while mucous membrane, eye, ear nose throat (ENT) and renal manifestations were often documented in PR3-ANCA vasculitis. ENT manifestation was also frequently observed in ANCA-negative vasculitis. However, there were no significant differences in pulmonary and nervous system manifestations among 3 AAV categories. There were no significant differences in cumulative relapse free survival according to the presence of MPO-ANCA or PR3-ANCA or no ANCA. Meanwhile, initial BVAS or BVAS for GPA ≥13.5 in MPO-ANCA vasculitis and initial FFS (1996) ≥1 in MPO-ANCA and ANCA-negative vasculitis were significant predictors of relapse of each AAV category. CONCLUSIONS: Clinical manifestations varied AAV categories, and neither MPO-ANCA nor PR3-ANCA significantly affected relapse of AAV. Initial BVAS or BVAS for GPA and FFS (1996) helped to predict relapse of specified AAV categories.
[Mh] Termos MeSH primário: Síndrome de Churg-Strauss/sangue
Granulomatose com Poliangiite/sangue
Poliangiite Microscópica/sangue
Mieloblastina/imunologia
Peroxidase/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos Anticitoplasma de Neutrófilos
Biomarcadores/sangue
Síndrome de Churg-Strauss/diagnóstico
Síndrome de Churg-Strauss/imunologia
Síndrome de Churg-Strauss/terapia
Intervalo Livre de Doença
Feminino
Granulomatose com Poliangiite/diagnóstico
Granulomatose com Poliangiite/imunologia
Granulomatose com Poliangiite/terapia
Seres Humanos
Masculino
Poliangiite Microscópica/diagnóstico
Poliangiite Microscópica/imunologia
Poliangiite Microscópica/terapia
Meia-Idade
Projetos Piloto
Valor Preditivo dos Testes
Recidiva
Indução de Remissão
Estudos Retrospectivos
Fatores de Risco
Seul
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Biomarkers); EC 1.11.1.7 (Peroxidase); EC 3.4.21.76 (Myeloblastin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE


  8 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28339359
[Au] Autor:Reynolds TD; Armstrong C; Ramanan AV
[Ad] Endereço:Department of Rheumatology/Medical Education, North Bristol NHS Trust, Bristol, UK. timothy.reynolds@nbt.nhs.uk.
[Ti] Título:Cardiac involvement as a presenting feature of eosinophilic granulomatosis with polyangiitis in childhood.
[So] Source:Clin Exp Rheumatol;35 Suppl 103(1):225, 2017 Mar-Apr.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome de Churg-Strauss/complicações
Granulomatose com Poliangiite/complicações
Cardiopatias/etiologia
Derrame Pericárdico/etiologia
[Mh] Termos MeSH secundário: Adolescente
Idade de Início
Antibacterianos/uso terapêutico
Broncodilatadores/uso terapêutico
Síndrome de Churg-Strauss/diagnóstico por imagem
Síndrome de Churg-Strauss/tratamento farmacológico
Feminino
Glucocorticoides/uso terapêutico
Granulomatose com Poliangiite/diagnóstico por imagem
Granulomatose com Poliangiite/tratamento farmacológico
Cardiopatias/diagnóstico por imagem
Cardiopatias/tratamento farmacológico
Seres Humanos
Imunossupressores/uso terapêutico
Derrame Pericárdico/diagnóstico por imagem
Derrame Pleural/diagnóstico por imagem
Derrame Pleural/etiologia
Tomografia Computadorizada por Raios X
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bronchodilator Agents); 0 (Glucocorticoids); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170923
[Lr] Data última revisão:
170923
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE


  9 / 1892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28281453
[Au] Autor:Oommen E; Hummel A; Allmannsberger L; Cuthbertson D; Carette S; Pagnoux C; Hoffman GS; Jenne DE; Khalidi NA; Koening CL; Langford CA; McAlear CA; Moreland L; Seo P; Sreih A; Ytterberg SR; Merkel PA; Specks U; Monach PA; Vasculitis Clinical Research Consortium
[Ad] Endereço:Section of Rheumatology, Boston University School of Medicine, Boston, MA; and Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA, USA.
[Ti] Título:IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
[So] Source:Clin Exp Rheumatol;35 Suppl 103(1):98-101, 2017 Mar-Apr.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the prevalence of anti-myeloperoxidase (MPO) antibodies of IgA (IgA anti-MPO) isotype in patients with eosinophilic granulomatosis with polyangiitis (EGPA), and the association of the IgA antibodies with IgG anti-MPO and with disease activity. METHODS: Serum samples from patients with EGPA followed in a multicenter longitudinal cohort were tested by ELISA for the presence of IgA anti-MPO and IgG anti-MPO antibodies. Sera from 87 healthy controls were used to define a positive test. Sera from 168 patients with EGPA (298 samples) were tested. Frequencies of positive testing for IgA anti-MPO were compared between patients with active EGPA, patients in remission, and controls. RESULTS: IgA anti-MPO was detected in 10 of 168 (6%) patients with EGPA (11 of 298 serum samples) compared to 1 of 87 (1%) healthy controls (p=0.10). All 11 samples testing positive for IgA anti-MPO also tested positive for IgG anti-MPO. Ninety samples tested positive for IgG anti-MPO but negative for IgA. Samples taken during active EGPA were positive for IgA anti-MPO in 6/72 cases (8%), compared to 5/226 (2%) during remission (p=0.03). Among samples taken during moderate or high disease activity, 5/41 were positive (12%, p=0.01 compared to remission). CONCLUSIONS: Although IgA anti-MPO antibodies are detectable in some patients with EGPA and may be detectable more frequently during active disease, their presence seems unlikely to provide information beyond what is obtained from conventional IgG anti-MPO.
[Mh] Termos MeSH primário: Anticorpos Anticitoplasma de Neutrófilos/sangue
Síndrome de Churg-Strauss/sangue
Imunoglobulina A/sangue
Imunoglobulina G/sangue
Peroxidase/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores/sangue
Canadá
Estudos de Casos e Controles
Síndrome de Churg-Strauss/diagnóstico
Síndrome de Churg-Strauss/tratamento farmacológico
Síndrome de Churg-Strauss/imunologia
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Imunossupressores/uso terapêutico
Masculino
Meia-Idade
Valor Preditivo dos Testes
Indução de Remissão
Resultado do Tratamento
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Biomarkers); 0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Immunosuppressive Agents); EC 1.11.1.7 (Peroxidase)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170720
[Lr] Data última revisão:
170720
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE


  10 / 1892 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28255916
[Au] Autor:Kanecki K; Nitsch-Osuch A; Gorynski P; Tarka P; Tyszko P
[Ad] Endereço:Department of Social Medicine and Public Health, Medical University of Warsaw, Oczki Str. 3, 02-007, Warsaw, Poland. kanecki@mp.pl.
[Ti] Título:Hospital Morbidity Database for Epidemiological Studies on Churg-Strauss Syndrome.
[So] Source:Adv Exp Med Biol;980:19-25, 2017.
[Is] ISSN:0065-2598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Churg-Strauss syndrome or more accurately eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel necrotizing vasculitis with a characteristic late-onset allergic rhinitis and asthma. The use of hospital morbidity database is an important element of the epidemiological analysis of this rare disease. The present study was undertaken to assess the incidence of EGPA and factors related to its epidemiology in Poland; the first analysis of the kind in Poland, enabling a comparison in the European context. This is a retrospective, population-based study using hospital discharge records with EGPA diagnosis, collected for a National Institute of Public Health survey covering the period from 2008 to 2013. The group consisted of 344 patients (206 females and 138 males) with the first-time hospitalization for EGPA. The major findings are that the annual incidence of EGPA in Poland was 1.5 per million (95% confidence intervals: 1.2-1.8), with the point prevalence of 8.8 per million at the end of 2013. A greater incidence of EGPA was observed in the regions with urban predominance. We conclude that discharge records may be a useful element of epidemiological studies on EGPA.
[Mh] Termos MeSH primário: Síndrome de Churg-Strauss/epidemiologia
[Mh] Termos MeSH secundário: Feminino
Hospitais
Seres Humanos
Masculino
Meia-Idade
Morbidade
Polônia/epidemiologia
Prevalência
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.1007/5584_2017_8



página 1 de 190 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde